Vancouver, Canada – November 7, 2025 – Onco-Innovations Limited (CBOE CA: ONCO) (Frankfurt: W1H, WKN: A3EKSZ)(OTCQB: ONNVF) ("Onco" or the "Company") is pleased to announce that its subsidiary, Inka Health Corp. ("Inka Health"), has published a technical primer[1] on the transportability of real-world evidence (RWE) titled Transportability of Non-Local Real-World Evidence and Its Relevance to Health Technology Assessment in the Journal of Clinical Evaluative Research (JCER). This primer, co-authored with experts at AstraZeneca Canada, addresses a critical challenge in global healthcare decision-making by demonstrating how advanced statistical transportability methods can adapt medical evidence from one country for use in another. These methods have the potential to accelerate regulatory approvals and improve patient access to innovative therapies, particularly in rare diseases where local data are often limited.

The primer outlines the three foundational principles required for reliable cross-border evidence sharing, which are consistency, positivity, and conditional exchangeability. By applying these golden rules, global regulators, health technology assessment bodies, and industry stakeholders gain a practical framework to evaluate the relevance of non-local RWE. The article also details proven statistical techniques including matching, weighting, standardization, and bias analysis that will be integrated into Inka Health’s SynoGraph platform to address differences in patient populations. This ensures that real-world oncology data from various regions can be more confidently used to inform healthcare decisions worldwide.

These approaches are especially important for rare disease drug approvals where patient populations are small and local evidence is often lacking. By enabling non-local data to be used effectively, the primer offers a potential solution to this bottleneck, ultimately helping to speed up approval of access to life-saving treatments. By incorporating these transportability methods into SynoGraph, Inka Health is advancing the use of artificial intelligence to overcome global data challenges in oncology, supporting more precise, timely, and evidence-based treatment decisions worldwide.

“This primer marks a pivotal step toward making global health data more accessible and actionable. By harnessing advanced statistical methods alongside AI-powered tools like SynoGraph, we can break down geographic barriers in oncology research. This publication is instrumental in exploring applications for transportability in real-world oncology settings and finding ways to help accelerate the delivery of innovative treatments to patients who need them most, particularly in rare disease communities where data scarcity has long been a challenge,” stated Paul Arora, Co-Founder of Inka Health.

AstraZeneca Canada became a client of Inka Health on September 23, 2024, prior to Inka Health becoming part of Onco-Innovations on February 3, 2025. AstraZeneca is not an investor in Onco-Innovations.  Any references to AstraZeneca Canada are only to the real-world evidence and analytic methods publications being developed under the services agreement with Inka Health.

About Inka Health

Inka Health is an AI-driven analytics company revolutionizing oncology research and drug development through advanced causal AI. Its proprietary platform, SynoGraph, leverages AI-powered causal inference to identify which cancer patients are most likely to respond to specific treatments, advancing precision medicine. By integrating diverse multimodal medical data, including genomics, transcriptomics, and proteomics, SynoGraph uncovers hidden insights that can optimize treatment decisions and clinical trial design. With this cutting-edge technology, Inka Health aims to help pharmaceutical companies accelerate drug development, reduce trial failures, and bring life-saving therapies to market faster.

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

“Thomas O’Shaughnessy”

Chief Executive Officer

For more information, please contact:

Thomas O’Shaughnessy

Chief Executive Officer

Tel: + 1 888 261 8055

investors@oncoinnovations.com

Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the Company’s business and plans, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “potential”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to receive regulatory approval in respect of the Private Placement, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward- looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

[1] A primer is an introductory text that provides a basic explanation of a subject, designed to help readers gain a foundational understanding.